Table 2.
Clinicopathological characteristics and CT findings of COVID-19 patients and controls
| Variable | COVID-19 patients |
Control (n=50) Mean±SD |
||
|---|---|---|---|---|
| Moderate (n=98) Mean±SD |
Severe (n=52) Mean±SD |
Total (n=150) Mean±SD |
||
| Age, years | 48.36±9.14 | 50.40±9.06 | 49.43±9.10 | 45.80±8.82 |
| Gender, n (%) | ||||
| Male | 56 (57.2%) | 33 (63.5%) | 89 (59.3%) | 32 (64%) |
| Female | 42 (42.8%) | 19 (36.5%) | 61 (40.7%) | 18 (36%) |
| Mortality, n (%) | 9 (9.2%) | 17 (32.7%) | 26 (17.3%) | – |
| Chest CT findings, n (%) | ||||
| Normal | 36 (37%) | 0 (0%) | 36 (24%) | – |
| Ground-glass opacity | 61 (62%) | 18 (35%) | 79 (53%) | |
| Ground-glass opacity with consolidation | 1 (1%) | 34 (65%) | 35 (23%) | |
| AST, U/L | 33.15±21.97 | 38.28±37.65a,c | 31.12±31.12 | 22.05±9.37 |
| ALT, U/L | 34.44±23.56a,c | 35.0±30.79a,c | 34.73±27.42a,c | 19.35±7.71 |
| Urea, mg/dL | 40.71±14.48a,c | 41.35±15.20a,c | 41.05±14.77a,c | 32.05±6.57 |
| Creatinine, mg/dL | 1.22±0.35a,c | 1.18±0.34a,c | 1.20±0.34a,c | 0.93±0.22 |
| CRP, mg/dL | 75.04±39.50b,c | 78.97±23.31b,c | 77.10±31.88b,c | 4.99±1.57 |
| WBC, 103/μL | 10.03±4.17a,c,b,e | 14.38±6.06b,c,d | 12.32±5.66b,c | 7.47±2.05 |
| Neutrophils, % | 73.76±7.19b,c,d | 79.26±5.57b,c,d | 76.65±6.92b,c | 65.00±5.06 |
| Lymphocytes, % | 19.89± 6.94b,c,d | 14.21±5.13b,c,d | 16.91±6.66b,c | 29.60±5.30 |
| D-dimer, mg/L | 0.43±0.35b,e | 2.64±3.34b,c,d | 1.59±2.66a,c | 0.06±0.01 |
| Ferritin, ng/mL | 213.86±135.24a,c,b,e | 494.11±260.96b,c,d | 361.0±252.47b,c | 104.35±50.85 |
aSignificant at p value <0.05.
bHighly significant at p value <0.001.
c
Significant difference versus control group.
d
Significant difference versus moderate group.
e
Significant difference versus severe group.